0001104659-20-131240.txt : 20201202 0001104659-20-131240.hdr.sgml : 20201202 20201202060115 ACCESSION NUMBER: 0001104659-20-131240 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20201201 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201202 DATE AS OF CHANGE: 20201202 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UNITED THERAPEUTICS Corp CENTRAL INDEX KEY: 0001082554 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 521984749 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26301 FILM NUMBER: 201362318 BUSINESS ADDRESS: STREET 1: 1040 SPRING ST CITY: SILVER SPRING STATE: MD ZIP: 20910 BUSINESS PHONE: 3016089292 MAIL ADDRESS: STREET 1: 1040 SPRING ST CITY: SILVER SPRING STATE: MD ZIP: 20910 FORMER COMPANY: FORMER CONFORMED NAME: UNITED THERAPEUTICS CORP DATE OF NAME CHANGE: 19990324 8-K 1 tm2037326d1_8k.htm FORM 8-K
0001082554 false 0001082554 2020-12-01 2020-12-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  December 1, 2020

 

United Therapeutics Corporation

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware   000-26301   52-1984749
(State or Other   (Commission   (I.R.S. Employer
Jurisdiction of   File Number)   Identification Number)
Incorporation)        

 

 

1040 Spring Street    
Silver Spring, MD   20910
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (301) 608-9292

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which
registered
Common Stock, par value $0.01 per share   UTHR   Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company      ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

  

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

As previously reported, on June 27, 2018, United Therapeutics Corporation (the “Company”) entered into a Credit Agreement (the “Credit Agreement”) with certain of its subsidiaries party thereto, as guarantors (the “Guarantors”), the lenders referred to therein (the “Lenders”), and Wells Fargo Bank, National Association (“Wells Fargo”), as administrative agent and as a swingline lender. The Credit Agreement provides for (i) an unsecured revolving credit facility of up to $1.0 billion; and (ii) a second unsecured revolving credit facility of up to $500 million (which facilities may, subject to obtaining commitments from existing or new lenders for such increase and subject to other conditions, be increased by up to $300 million in the aggregate). The facilities were originally scheduled to mature five years after the closing date of the Credit Agreement, on June 27, 2023, subject to an ability of the Lenders thereunder, or certain of the Lenders thereunder, to elect to extend the maturity date of their commitments by one year following a request for such extension by the Company in accordance with the terms of the Credit Agreement, up to a maximum of two such extensions. As previously reported, on June 27, 2019, the Company and the Lenders agreed to extend the maturity of the commitments and loans of each Lender under the Credit Agreement for one year, to June 27, 2024.

 

On December 1, 2020, the Company, Wells Fargo and the Lenders entered into a Second Amendment to Credit Agreement (the “Second Amendment”), which extends the maturity of the commitments and loans of each Lender under the Credit Agreement to the date that is five years after the closing date of the Second Amendment, which is December 1, 2025.

 

The foregoing summary is qualified by reference to the copy of the Second Amendment attached hereto as Exhibit 10.2.

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The information set forth in Item 1.01 of this Current Report on Form 8-K regarding the extension of the Credit Agreement is incorporated herein by reference.

 

Item 9.01. Exhibits

 

On November 2, 2018, the Company, Wells Fargo and the Lenders entered into a First Amendment to Credit Agreement (the “First Amendment”), which made certain changes to the definition of “Consolidated EBITDA” in the Credit Agreement. 

 

(d)  Exhibits
     
Exhibit No.   Description of Exhibit
     
10.1   First Amendment to Credit Agreement, dated as of November 2, 2018, by and among United Therapeutics Corporation, certain of its subsidiaries party thereto, as guarantors, the lenders referred to therein, and Wells Fargo Bank, National Association, as administrative agent and as a swingline lender.
     
10.2   Second Amendment to Credit Agreement, dated as of December 1, 2020, by and among United Therapeutics Corporation, certain of its subsidiaries party thereto, as guarantors, the lenders referred to therein, and Wells Fargo Bank, National Association, as administrative agent and as a swingline lender. 
     
101   The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

  UNITED THERAPEUTICS CORPORATION
     
     
Dated: December 2, 2020 By: /s/ Paul A. Mahon
  Name: Paul A. Mahon
  Title: General Counsel

 

 

 

 EX-10.1 2 tm2037326d1_ex10-1.htm EXHIBIT 10.1

 

Exhibit 10.1

 

FIRST AMENDMENT TO CREDIT AGREEMENT

 

THIS FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) dated as of November 2, 2018 is by and among UNITED THERAPEUTICS CORPORATION, a Delaware corporation (the “Borrower”), the Guarantors, the Lenders party hereto and WELLS FARGO BANK, NATIONAL ASSOCIATION, a national banking association, as the Administrative Agent (in such capacity, “Administrative Agent”).

 

W I T N E S S E T H

 

WHEREAS, the Borrower, the Guarantors party thereto, the Lenders from time to time party thereto and the Administrative Agent are party to that certain Credit Agreement, dated as of June 27, 2018 (as amended, restated, extended, supplemented or otherwise modified from time to time, the “Credit Agreement”; capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed thereto in the Credit Agreement, as amended hereby);

 

WHEREAS, the Borrower has requested that the Lenders approve certain amendments to the Credit Agreement; and

 

WHEREAS, the Required Lenders have approved the Borrower’s requested amendments on the terms and conditions set forth herein.

 

NOW, THEREFORE, IN CONSIDERATION of the premises and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

1.            Defined Terms. Capitalized terms used herein but not otherwise defined herein shall have the meanings provided to such terms in the Credit Agreement.

 

2.            Amendment. The definition of “Consolidated EBITDA” in Section 1.1 of the Credit Agreement is hereby amended and restated in its entirety as follows:

 

“Consolidated EBITDA” means, for any period, the sum of the following determined on a Consolidated basis, without duplication, for the Borrower and its Subsidiaries in accordance with GAAP: (a) Consolidated Net Income for such period plus (b) the sum of the following, without duplication, to the extent deducted in determining Consolidated Net Income for such period: (i) income and franchise taxes, (ii) Consolidated Interest Expense, (iii) amortization and depreciation, (iv) stock based compensation expense (including with respect to stock option, share tracking award and employee stock purchase plans), (v) non-cash license fee charges and other non-cash charges (or minus non-cash adjustments increasing Consolidated Net Income) recorded in respect to purchase accounting adjustments, (vi) non-cash asset impairment charges, (vii) non-recurring non-cash charges reducing Consolidated Net Income in such period (excluding any such expenses or charges to the extent representing an accrual or reserve for any cash charge in any future period and excluding write-downs of current assets), (viii) non-recurring transaction fees, costs and expenses, integration, reorganization and restructuring costs and facility consolidation and closing costs incurred in connection with reorganizations, restructurings, Investments and other acquisitions or inbound licenses of any rights in respect of (including any collaboration or development agreements with respect to) drug or pharmaceutical products or other technologies (and any related property or assets) (including, the incurrence or repayment of Indebtedness in connection therewith) and Asset Dispositions permitted hereunder, provided that (A) such fees, costs and expenses in this clause (viii) are incurred within twelve (12) months of the occurrence of such applicable triggering event and (B) the aggregate amount of such fees, costs and expenses added back pursuant to this clause (viii) shall not exceed the greater of (1) 15% of Consolidated EBITDA for the applicable period of four fiscal quarters (prior to giving effect to such adjustments) and (2) $100,000,000 during any such applicable period of four fiscal quarters, (ix) any upfront payments and any milestone payments or other deferred consideration (including purchase price adjustments, earn-outs, compensation, contingent value rights, non-compete payments and similar obligations but excluding ongoing royalty payments), contingent or non-contingent, accrued or paid during such period, and any buy-down of royalty obligations, in each case in respect of acquisitions or inbound licenses of any rights in respect of (including any collaboration or development agreements with respect to) drug or pharmaceutical products or other technologies (and any related property or assets), and (x) losses (or minus gains) associated with the revaluation of any milestone payments or other deferred consideration referred to in clause (ix) above, less (c) to the extent included in determining Consolidated Net Income for such period, (i) interest income and (ii) all non-recurring non-cash items increasing Consolidated Net Income. For purposes of this Agreement, Consolidated EBITDA shall be adjusted on a Pro Forma Basis.

 

 

 

 

3.            Conditions Precedent. The effectiveness of this Amendment shall be subject to receipt by the Administrative Agent of counterparts of this Amendment duly executed by the Borrower, each Guarantor, the Required Lenders and the Administrative Agent.

 

4.            Amendment is a “Loan Document”. This Amendment is a Loan Document and all references to a “Loan Document” in the Credit Agreement and the other Loan Documents shall be deemed to include this Amendment.

 

5.            Reaffirmation of Obligations. Each Credit Party hereby ratifies the Credit Agreement, as amended hereby, and each other Loan Document to which it is a party and acknowledges and reaffirms (a) that it is bound by all terms of the Credit Agreement, as amended hereby, and each other Loan Document to which it is a party applicable to it and (b) that it is responsible for the observance and full performance of its respective obligations under the Loan Documents.

 

6.            No Other Changes. Except as modified hereby, all of the terms and provisions of the Loan Documents shall remain in full force and effect.

 

7.            Expenses. The Borrower agrees to pay all reasonable costs and expenses incurred by the Administrative Agent in connection with the preparation, execution and delivery of this Agreement, including without limitation the reasonable fees and expenses of the Administrative Agent’s legal counsel.

 

8.            Counterparts; Delivery. This Amendment may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page of this Amendment by facsimile or in electronic (i.e., “pdf” or “tif”) format shall be effective as delivery of a manually executed counterpart of this Amendment.

 

9.            Governing Law. This Amendment and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Amendment and the transactions contemplated hereby shall be governed by, and construed in accordance with, the law of the State of New York.

 

[Signature Pages Follow]

 

 

 

 

IN WITNESS WHEREOF, each of the parties hereto has caused a counterpart of this Amendment to be duly executed and delivered as of the date first above written.

 

BORROWER: UNITED THERAPEUTICS CORPORATION,
  a Delaware corporation
   
  By: /s/ James Edgemond
  Name: James Edgemond
  Title: Chief Financial Officer and Treasurer
   
GUARANTORS: LUNG BIOTECHNOLOGY PBC,
  a Delaware public benefit corporation
   
  By: /s/ James Edgemond
  Name: James Edgemond
  Title: Chief Financial Officer and Treasurer

 

UNITED THERAPEUTICS CORPORATION

First Amendment to CREDIT AGREEMENT

 

 

 

 

AGENTS AND LENDERS: WELLS FARGO BANK, NATIONAL ASSOCIATION, 
  as Administrative Agent,
  Swingline Lender and Lender
   
  By: /s/ Kirk Tesch
  Name: Kirk Tesch
  Title: Managing Director

 

UNITED THERAPEUTICS CORPORATION

First Amendment to CREDIT AGREEMENT

 

 

 

 

  BANK OF AMERICA, N.A.,
  as Lender
   
  By: /s/ H. Hope Walker
  Name: H. Hope Walker
  Title: Senior Vice President

 

UNITED THERAPEUTICS CORPORATION

First Amendment to CREDIT AGREEMENT

 

 

 

 

  DNB Capital LLC,
  as Lender
   
  By: /s/ Kristie Li
  Name: Kristie Li
  Title: Senior Vice President
   
  By: /s/ Kristi Birkeland Sorensen
  Name: Kristi Birkeland Sorensen
  Title: Head of Corporate Banking

 

UNITED THERAPEUTICS CORPORATION

First Amendment to CREDIT AGREEMENT

 

 

 

 

  MUFG Bank, Ltd.,
  as Lender
   
  By: /s/ Kevin Wood
  Name: Kevin Wood
  Title: Director

 

UNITED THERAPEUTICS CORPORATION

First Amendment to CREDIT AGREEMENT

 

 

 

 

  PNC BANK, NATIONAL ASSOCIATION,
  as Lender
   
  By: /s/ Carolyn L. West
  Name: Carolyn L. West
  Title: Senior Vice President

 

UNITED THERAPEUTICS CORPORATION

First Amendment to CREDIT AGREEMENT

 

 

 

 

  Citibank, N.A.,
  as Lender
   
  By: /s/ Pranjal Gambhir
  Name: Pranjal Gambhir
  Title: Vice President

 

UNITED THERAPEUTICS CORPORATION

First Amendment to CREDIT AGREEMENT

 

 

 

 

  Barclays Bank PLC,
  as Lender
   
  By: /s/ Jonathan Stone
  Name: Jonathan Stone
  Title: Director
  Date: 11.2.18
  Executed in New York

 

Restricted - Internal

 

UNITED THERAPEUTICS CORPORATION

First Amendment to CREDIT AGREEMENT

 

 

 

 

  HSBC Bank USA, National Association, 
  as Lender
   
  By: /s/ John Treadwell
  Name: John P. Treadwell Jr.
  Title: SVP

 

UNITED THERAPEUTICS CORPORATION

First Amendment to CREDIT AGREEMENT

 

 

 

 

  State Bank of India, New York,
  as Lender
   
  By: /s/ Manoranjan Panda
  Name: Mr. Manoranjan Panda
  Title: Vice President & Head (Credit)

 

[SEAL]

 

UNITED THERAPEUTICS CORPORATION

First Amendment to CREDIT AGREEMENT

 

 

 

 

  JPMorgan Chase Bank, N.A.,
  as Lender
   
  By: /s/ Anthony Galea
  Name: Anthony Galea
  Title: Executive Director

 

UNITED THERAPEUTICS CORPORATION

First Amendment to CREDIT AGREEMENT

 

 

 

 EX-10.2 3 tm2037326d1_ex10-2.htm EXHIBIT 10.2

 

Exhibit 10.2

 

EXECUTION VERSION

 

SECOND AMENDMENT TO CREDIT AGREEMENT

 

THIS SECOND AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) dated as of December 1, 2020 is by and among UNITED THERAPEUTICS CORPORATION, a Delaware corporation (the “Borrower”), the Guarantors party hereto, the Lenders party hereto and WELLS FARGO BANK, NATIONAL ASSOCIATION, a national banking association, in its capacities as the Administrative Agent and the Swingline Lender.

 

W I T N E S S E T H

 

WHEREAS, the Borrower, the Guarantors party thereto, the Lenders from time to time party thereto and Wells Fargo Bank, National Association, a national banking association, in its capacities as the Administrative Agent and the Swingline Lender, are party to that certain Credit Agreement, dated as of June 27, 2018 (as amended, restated, extended, supplemented or otherwise modified from time to time, the “Credit Agreement”);

 

WHEREAS, the Borrower has requested that the Lenders approve certain amendments to the Credit Agreement; and

 

WHEREAS, the Lenders party hereto have approved the Borrower’s requested amendments on the terms and conditions set forth herein.

 

NOW, THEREFORE, IN CONSIDERATION of the premises and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

1.             Defined Terms. Capitalized terms used herein but not otherwise defined herein shall have the meanings provided to such terms in the Credit Agreement.

 

2.             Amendments.

 

(a)           The definition of “Bail-In Action” in Section 1.1 of the Credit Agreement is hereby amended and restated in its entirety as follows:

 

“Bail-In Action” means the exercise of any Write-Down and Conversion Powers by the applicable Resolution Authority in respect of any liability of an Affected Financial Institution.

 

(b)           The definition of “Bail-In Legislation” in Section 1.1 of the Credit Agreement is hereby amended and restated in its entirety as follows:

 

“Bail-In Legislation” means (a) with respect to any EEA Member Country implementing Article 55 of Directive 2014/59/EU of the European Parliament and of the Council of the European Union, the implementing law, regulation, rule or requirement for such EEA Member Country from time to time which is described in the EU Bail-In Legislation Schedule, and (b) with respect to the United Kingdom, Part I of the United Kingdom Banking Act 2009 (as amended from time to time) and any other law, regulation or rule applicable in the United Kingdom relating to the resolution of unsound or failing banks, investment firms or other financial institutions or their affiliates (other than through liquidation, administration or other insolvency proceedings).

 

 

 

(c)            The definition of “Revolving A Credit Maturity Date” in Section 1.1 of the Credit Agreement is hereby amended and restated in its entirety as follows:

 

“Revolving A Credit Maturity Date” means the earliest to occur of (a) December 1, 2025, (b) the date of termination of the Revolving A Credit Commitments by the Borrower pursuant to Section 2.5, and (c) the date of termination of the Revolving A Credit Commitments pursuant to Section 8.2(a).

 

(d)           The definition of “Revolving B Credit Maturity Date” in Section 1.1 of the Credit Agreement is hereby amended and restated in its entirety as follows:

 

“Revolving B Credit Maturity Date” means, with respect to each Revolving B Credit Lender, the earliest to occur of (a) December 1, 2025, (b) the date of termination of the Revolving B Credit Commitments by the Borrower pursuant to Section 2.5, and (c) the date of termination of the Revolving B Credit Commitments pursuant to Section 8.2(a).

 

(e)            The definition of “Write-Down and Conversion Powers” in Section 1.1 of the Credit Agreement is hereby amended and restated in its entirety as follows:

 

“Write-Down and Conversion Powers” means (a) with respect to any EEA Resolution Authority, the write-down and conversion powers of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule, and (b) with respect to the United Kingdom, any powers of the applicable Resolution Authority under the Bail-In Legislation to cancel, reduce, modify or change the form of a liability of any UK Financial Institution or any contract or instrument under which that liability arises, to convert all or part of that liability into shares, securities or obligations of that person or any other person, to provide that any such contract or instrument is to have effect as if a right had been exercised under it or to suspend any obligation in respect of that liability or any of the powers under that Bail-In Legislation that are related to or ancillary to any of those powers.

 

(f)            The following defined terms are hereby added to Section 1.1 of the Credit Agreement in the appropriate alphabetical order:

 

“Affected Financial Institution” means (a) any EEA Financial Institution or (b) any UK Financial Institution.

 

“BHC Act Affiliate” of a party means an “affiliate” (as such term is defined under, and interpreted in accordance with, 12 U.S.C. 1841(k)) of such party.

 

“Covered Entity” means any of the following: (a) a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b); (b) a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or (c) a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b).

 

“Covered Party” has the meaning assigned thereto in Section 11.25.

 

2

 

 

“Default Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable.

 

“Electronic Record” has the meaning assigned to that term in, and shall be interpreted in accordance with, 15 U.S.C. 7006.

 

“Electronic Signature” has the meaning assigned to that term in, and shall be interpreted in accordance with, 15 U.S.C. 7006.

 

“QFC” has the meaning assigned to the term “qualified financial contract” in, and shall be interpreted in accordance with, 12 U.S.C. 5390(c)(8)(D).

 

“QFC Credit Support” has the meaning assigned thereto in Section 11.25.

 

“Resolution Authority” means an EEA Resolution Authority or, with respect to any UK Financial Institution, a UK Resolution Authority.

 

“Supported QFC” has the meaning assigned thereto in Section 11.25.

 

“UK Financial Institution” means any BRRD Undertaking (as such term is defined under the PRA Rulebook (as amended from time to time) promulgated by the United Kingdom Prudential Regulation Authority) or any person falling within IFPRU 11.6 of the FCA Handbook (as amended from time to time) promulgated by the United Kingdom Financial Conduct Authority, which includes certain credit institutions and investment firms, and certain affiliates of such credit institutions or investment firms.

 

“UK Resolution Authority” means the Bank of England or any other public administrative authority having responsibility for the resolution of any UK Financial Institution.

 

“U.S. Special Resolution Regimes” has the meaning assigned thereto in Section 11.25.

 

(g)           The following defined terms are hereby deleted from Section 1.1 of the Credit Agreement: Anniversary Date; Current Revolving A Credit Maturity Date; Current Revolving B Credit Maturity Date; Extending Revolving A Credit Lender; Extending Revolving B Credit Lender; Extension Letter; Non-Extending Revolving A Credit Lender; Non-Extending Revolving B Credit Lender; Notice Date; Scheduled Revolving A Credit Maturity Date; and Scheduled Revolving B Credit Maturity Date.

 

(h)           Article I of the Credit Agreement is hereby amended to add a new Section 1.10 immediately following Section 1.9 of the Credit Agreement as follows:

 

Section 1.10          Divisions. For all purposes under the Loan Documents, in connection with any division or plan of division under Delaware law (or any comparable event under a different jurisdiction’s laws): (a) if any asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then it shall be deemed to have been transferred from the original Person to the subsequent Person, and (b) if any new Person comes into existence, such new Person shall be deemed to have been organized on the first date of its existence by the holders of its Equity Interests at such time.

 

3

 

 

(i)            Section 2.7 of the Credit Agreement is hereby amended and restated in its entirety as follows:

 

Section 2.7            [Reserved].

 

(j)            The text of Section 3.12(b) of the Credit Agreement prior to the first proviso thereof is hereby amended and restated in its entirety as follows:

 

If any Lender requests compensation under Section 3.10, or if the Borrower is required to pay any Indemnified Taxes or additional amounts to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 3.11, and, in each case, such Lender has declined or is unable to designate a different Lending Office in accordance with Section 3.12(a), or if any Lender is a Defaulting Lender or a Non-Consenting Lender, then the Borrower may, at its sole expense and effort, upon notice to such Lender and the Administrative Agent, require such Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions contained in, and consents required by, Section 11.9), all of its interests, rights (other than its existing rights to payments pursuant to Section 3.10 or Section 3.11) and obligations under this Agreement and the related Loan Documents to an Eligible Assignee that shall assume such obligations (which assignee may be another Lender, if a Lender accepts such assignment);

 

(k)           Section 5.20 of the Credit Agreement is hereby amended and restated in its entirety as follows:

 

Section 5.20          No Affected Financial Institution. No Credit Party is an Affected Financial Institution.

 

(l)            Section 11.16(b) of the Credit Agreement is hereby amended and restated in its entirety as follows:

 

(b)           Electronic Execution. The words “execute,” “execution,” “signed,” “signature,” “delivery” and words of like import in or related to this Agreement, any other Loan Document or any document, amendment, approval, consent, waiver, modification, information, notice, certificate, report, statement, disclosure, or authorization to be signed or delivered in connection with this Agreement or any other Loan Document or the transactions contemplated hereby shall be deemed to include Electronic Signatures or execution in the form of an Electronic Record, and contract formations on electronic platforms approved by the Administrative Agent, deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any Applicable Law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act. Each party hereto agrees that any Electronic Signature or execution in the form of an Electronic Record shall be valid and binding on itself and each of the other parties hereto to the same extent as a manual, original signature. For the avoidance of doubt, the authorization under this paragraph may include use or acceptance by the parties of a manually signed paper which has been converted into electronic form (such as scanned into .pdf), or an electronically signed paper converted into another format, for transmission, delivery and/or retention. Notwithstanding anything contained herein to the contrary, the Administrative Agent is under no obligation to accept an Electronic Signature in any form or in any format unless expressly agreed to by the Administrative Agent pursuant to procedures approved by it; provided, that without limiting the foregoing, (i) to the extent the Administrative Agent has agreed to accept such Electronic Signature from any party hereto, the Administrative Agent and the other parties hereto shall be entitled to rely on any such Electronic Signature purportedly given by or on behalf of the executing party without further verification and (ii) upon the request of the Administrative Agent or any Lender, any Electronic Signature shall be promptly followed by an original manually executed counterpart thereof. Without limiting the generality of the foregoing, each party hereto hereby (A) agrees that, for all purposes, including in connection with any workout, restructuring, enforcement of remedies, bankruptcy proceedings or litigation among the Administrative Agent, the Lenders and any of the Credit Parties, electronic images of this Agreement or any other Loan Document (in each case, including with respect to any signature pages thereto) shall have the same legal effect, validity and enforceability as any paper original, and (B) waives any argument, defense or right to contest the validity or enforceability of the Loan Documents based solely on the lack of paper original copies of any Loan Documents, including with respect to any signature pages thereto.

 

4

 

 

(m)          Section 11.21 of the Credit Agreement is hereby amended and restated in its entirety as follows:

 

Section 11.21       Acknowledgement and Consent to Bail-In of Affected Financial Institutions. Notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that any liability of any Affected Financial Institution arising under any Loan Document, to the extent such liability is unsecured, may be subject to the Write-Down and Conversion Powers of the applicable Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by: (a) the application of any Write-Down and Conversion Powers by the applicable Resolution Authority to any such liabilities arising hereunder which may be payable to it by any party hereto that is an Affected Financial Institution; and (b) the effects of any Bail-In Action on any such liability, including, if applicable: (i) a reduction in full or in part or cancellation of any such liability; (ii) a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such Affected Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement or any other Loan Document; or (iii) the variation of the terms of such liability in connection with the exercise of the Write-Down and Conversion Powers of the applicable Resolution Authority.

 

(n)           Section 11.23 of the Credit Agreement is hereby amended and restated in its entirety as follows:

 

Section 11.23        Certain ERISA Matters.

 

(a)           Each Lender (x) represents and warrants, as of the date such Person became a Lender party hereto, to, and (y) covenants, from the date such Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of, the Administrative Agent, each Arranger and their respective Affiliates, and not, for the avoidance of doubt, to or for the benefit of the Borrower or any other Credit Party, that at least one of the following is and will be true:

 

(i)             such Lender is not using “plan assets” (within the meaning of Section 3(42) of ERISA or otherwise) of one or more Benefit Plans with respect to such Lender’s entrance into, participation in, administration of and performance of the Loans, the Commitments or this Agreement;

 

5

 

 

(ii)            the transaction exemption set forth in one or more PTEs, such as PTE 84-14 (a class exemption for certain transactions determined by independent qualified professional asset managers), PTE 95-60 (a class exemption for certain transactions involving insurance company general accounts), PTE 90-1 (a class exemption for certain transactions involving insurance company pooled separate accounts), PTE 91-38 (a class exemption for certain transactions involving bank collective investment funds) or PTE 96-23 (a class exemption for certain transactions determined by in-house asset managers), is applicable with respect to such Lender’s entrance into, participation in, administration of and performance of the Loans, the Commitments and this Agreement;

 

(iii)           (A) such Lender is an investment fund managed by a “Qualified Professional Asset Manager” (within the meaning of Part VI of PTE 84-14), (B) such Qualified Professional Asset Manager made the investment decision on behalf of such Lender to enter into, participate in, administer and perform the Loans, the Commitments and this Agreement, (C) the entrance into, participation in, administration of and performance of the Loans, the Commitments and this Agreement satisfies the requirements of sub-sections (b) through (g) of Part I of PTE 84-14 and (D) to the best knowledge of such Lender, the requirements of subsection (a) of Part I of PTE 84-14 are satisfied with respect to such Lender’s entrance into, participation in, administration of and performance of the Loans, the Commitments and this Agreement; or

 

(iv)           such other representation, warranty and covenant as may be agreed in writing between the Administrative Agent, in its sole discretion, and such Lender.

 

(b)           In addition, unless either (1) sub-clause (i) in the immediately preceding clause (a) is true with respect to a Lender or (2) a Lender has provided another representation, warranty and covenant in accordance with sub-clause (iv) in the immediately preceding clause (a), such Lender further (x) represents and warrants, as of the date such Person became a Lender party hereto, to, and (y) covenants, from the date such Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of, the Administrative Agent, each Arranger and their respective Affiliates, and not, for the avoidance of doubt, to or for the benefit of the Borrower or any other Credit Party, that none of the Administrative Agent, any Arranger or any of their respective Affiliates is a fiduciary with respect to the assets of such Lender involved in such Lender’s entrance into, participation in, administration of and performance of the Loans, the Commitments and this Agreement (including in connection with the reservation or exercise of any rights by the Administrative Agent under this Agreement, any other Loan Document or any documents related hereto or thereto).

 

6

 

 

(o)           Article XI of the Credit Agreement is hereby amended to add a new Section 11.25 immediately following Section 11.24 of the Credit Agreement as follows:

 

Section 11.25       Acknowledgement Regarding Any Supported QFCs. To the extent that the Loan Documents provide support, through a guarantee or otherwise, for Hedge Agreements or any other agreement or instrument that is a QFC (such support, “QFC Credit Support” and, each such QFC, a “Supported QFC”), the parties acknowledge and agree that, with respect to the resolution power of the FDIC under the Federal Deposit Insurance Act and Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act (together with the regulations promulgated thereunder, the “U.S. Special Resolution Regimes”) in respect of such Supported QFC and QFC Credit Support (with the provisions below applicable notwithstanding that the Loan Documents and any Supported QFC may in fact be stated to be governed by the laws of the State of New York and/or of the United States or any other state of the United States), in the event a Covered Entity that is party to a Supported QFC (each, a “Covered Party”) becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer of such Supported QFC and the benefit of such QFC Credit Support (and any interest and obligation in or under such Supported QFC and such QFC Credit Support, and any rights in property securing such Supported QFC or such QFC Credit Support) from such Covered Party will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if the Supported QFC and such QFC Credit Support (and any such interest, obligation and rights in property) were governed by the laws of the United States or a state of the United States. In the event a Covered Party or a BHC Act Affiliate of a Covered Party becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under the Loan Documents that might otherwise apply to such Supported QFC or any QFC Credit Support that may be exercised against such Covered Party are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if the Supported QFC and the Loan Documents were governed by the laws of the United States or a state of the United States. Without limitation of the foregoing, it is understood and agreed that rights and remedies of the parties with respect to a Defaulting Lender shall in no event affect the rights of any Covered Party with respect to a Supported QFC or any QFC Credit Support.

 

(p)           Exhibit I to the Credit Agreement is hereby amended and restated in its entirety to read “[Reserved]”. The reference to Exhibit I in the table of contents of the Credit Agreement is hereby amended and restated in its entirety to read as follows:

 

Exhibit I             [Reserved]

 

7

 

 

3.             Conditions Precedent. The effectiveness of this Amendment shall be subject to the satisfaction of the following conditions precedent (the date such on which conditions precedent are satisfied being referred to herein as the “Second Amendment Effective Date”):

 

(a)           receipt by the Administrative Agent of counterparts of this Amendment duly executed by the Borrower, each Guarantor, the Lenders, the Administrative Agent, and the Swingline Lender;

 

(b)           immediately prior to giving effect to this Amendment, and after giving effect to this Amendment, (i) no Default or Event of Default shall exist or be continuing, and (ii) the representations and warranties of the Credit Parties contained in the Credit Agreement (as amended by this Amendment) and the other Loan Documents shall be true and correct in all material respects, except for any representation and warranty that is qualified by materiality or reference to Material Adverse Effect, which such representation and warranty shall be true and correct in all respects, on and as of the Second Amendment Effective Date with the same effect as if made on and as of the Second Amendment Effective Date (except for any such representation and warranty that by its terms is made only as of an earlier date, which representation and warranty shall remain true and correct in all material respects as of such earlier date, except for any representation and warranty that is qualified by materiality or reference to Material Adverse Effect, which such representation and warranty shall be true and correct in all respects as of such earlier date);

 

(c)           receipt by the Administrative Agent of a certificate from a Responsible Officer of the Borrower certifying as to the accuracy of the conditions set forth in Section 3(b);

 

(d)           the Borrower shall have paid, or made arrangements to pay, contemporaneously with the occurrence of the Second Amendment Effective Date, any fees or commissions due on or prior to the Second Amendment Effective Date pursuant to the Loan Documents or any fee letter entered into in connection with this Amendment;

 

(e)           each Credit Party shall have provided to the Administrative Agent and each Lender the documentation and other information requested by the Administrative Agent or such Lender in order to comply with requirements of the PATRIOT Act, applicable “know your customer” and anti-money laundering rules and regulations; and

 

(f)            if the Borrower qualifies as a “legal entity customer” under the Beneficial Ownership Regulation, the Borrower shall have delivered, to each Lender that so requests, a Beneficial Ownership Certification in relation to the Borrower.

 

For purposes of determining compliance with the conditions specified in this Section 3, each Lender that has signed this Amendment shall be deemed to have consented to, approved or accepted or to be satisfied with, each document or other matter required thereunder to be consented to or approved by or acceptable or satisfactory to a Lender unless the Administrative Agent shall have received notice from such Lender prior to the proposed Second Amendment Effective Date specifying its objection thereto.

 

4.             Amendment is a “Loan Document”. This Amendment is a Loan Document and all references to a “Loan Document” in the Credit Agreement and the other Loan Documents shall be deemed to include this Amendment.

 

8

 

 

5.             Reaffirmation of Obligations. Each Credit Party hereby ratifies the Credit Agreement, as amended hereby, and each other Loan Document to which it is a party and acknowledges and reaffirms (a) that it is bound by all terms of the Credit Agreement, as amended hereby, and each other Loan Document to which it is a party applicable to it and (b) that it is responsible for the observance and full performance of its respective obligations under the Loan Documents.

 

6.             Lender Representation and Warranty; Lender Covenant; Acknowledgement. Each Lender party hereto represents and warrants that, after giving effect to this Amendment, the representations and warranties of such Lender set forth in Section 11.23 of the Credit Agreement (as amended by this Amendment) are true and correct as of the Second Amendment Effective Date. Each Lender party hereto hereby agrees to comply with the covenants applicable to such Lender set forth in Section 11.23 of the Credit Agreement (as amended by this Amendment). Each party hereto acknowledges and agrees to the provisions set forth in Sections 11.16(b), 11.21 and 11.25 of the Credit Agreement (as amended by this Amendment).

 

7.             No Other Changes. Except as modified hereby, all of the terms and provisions of the Loan Documents shall remain in full force and effect.

 

8.             Expenses. The Borrower agrees to pay all reasonable costs and expenses incurred by the Administrative Agent in connection with the preparation, execution and delivery of this Amendment, including the reasonable fees and expenses of the Administrative Agent’s legal counsel.

 

9.             Counterparts; Delivery; Electronic Execution. This Amendment may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page of this Amendment by facsimile or in electronic (i.e., “pdf” or “tif”) format shall be effective as delivery of a manually executed counterpart of this Amendment. Subject to Section 11.16(b) of the Credit Agreement (as amended by this Amendment), this Amendment may be in the form of an Electronic Record (as defined in the Credit Agreement (as amended by this Amendment)), and may be executed using Electronic Signatures (as defined in the Credit Agreement (as amended by this Amendment)), including facsimile and .pdf, and shall be considered an original and shall have the same legal effect, validity and enforceability as a paper record.

 

10.           Governing Law. This Amendment and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Amendment and the transactions contemplated hereby shall be governed by, and construed in accordance with, the law of the State of New York.

 

[Signature Pages Follow]

 

9

 

 

IN WITNESS WHEREOF, each of the parties hereto has caused a counterpart of this Amendment to be duly executed and delivered as of the date first above written.

 

BORROWER: UNITED THERAPEUTICS CORPORATION,
  a Delaware corporation
   
  By: /s/ James Edgemond
  Name: James Edgemond
  Title: Chief Financial Officer and Treasurer
   
GUARANTORS: LUNG BIOTECHNOLOGY PBC,
  a Delaware public benefit corporation
   
  By: /s/ James Edgemond
  Name:  James Edgemond
  Title: Chief Financial Officer and Treasurer

 

UNITED THERAPEUTICS CORPORATION
SECOND AMENDMENT TO CREDIT AGREEMENT

 

 

 

ADMINISTRATIVE AGENT AND LENDERS: WELLS FARGO BANK, NATIONAL ASSOCIATION,
  as the Administrative Agent, the Swingline Lender and a Lender
   
  By: /s/ Kirk Tesch
  Name:  Kirk Tesch
  Title: Managing Director

 

UNITED THERAPEUTICS CORPORATION
SECOND AMENDMENT TO CREDIT AGREEMENT

 

 

 

  BANK OF AMERICA, N.A.,
  as a Lender
   
  By: /s/ H. Hope Walker
  Name:  H. Hope Walker
  Title: Senior Vice President

 

UNITED THERAPEUTICS CORPORATION
SECOND AMENDMENT TO CREDIT AGREEMENT

 

 

 

  DNB Capital LLC,
  as a Lender
   
  By: /s/ Mita Zalavadia
  Name: Mita Zalavadia
  Title: Assistant Vice President
   
  By: /s/ Ahelia Singh
  Name:   Ahelia Singh
  Title: Assistance Vice President

 

UNITED THERAPEUTICS CORPORATION
SECOND AMENDMENT TO CREDIT AGREEMENT

 

 

 

  MUFG Bank, Ltd.,
  as a Lender
   
  By: /s/ Jack Lonker
  Name:  Jack Lonker
  Title: Director

 

UNITED THERAPEUTICS CORPORATION
SECOND AMENDMENT TO CREDIT AGREEMENT

 

 

 

  PNC BANK, NATIONAL ASSOCIATION,
  as a Lender
   
  By: /s/ Eric H. Williams
  Name:  Eric H. Williams
  Title: Senior Vice President

 

UNITED THERAPEUTICS CORPORATION
SECOND AMENDMENT TO CREDIT AGREEMENT

 

 

 

  Citibank, N.A.,
  as a Lender
   
  By: /s/ Pranjal Gambhir
  Name:  Pranjal Gambhir
  Title: Vice President

 

UNITED THERAPEUTICS CORPORATION
SECOND AMENDMENT TO CREDIT AGREEMENT

 

 

 

  Barclays Bank PLC,
  as a Lender
   
  By: /s/ Robert F Komminsk
  Name:  Robert F Komminsk
  Title: Director
  Date: 11/23/2020

 

UNITED THERAPEUTICS CORPORATION
SECOND AMENDMENT TO CREDIT AGREEMENT

 

 

 

  HSBC Bank USA, National Association,
  as a Lender
   
  By: /s/ Kyle O’Reilly
  Name:  Kyle O’Reilly
  Title: Vice President

 

UNITED THERAPEUTICS CORPORATION
SECOND AMENDMENT TO CREDIT AGREEMENT

 

 

 

  State Bank of India, New York,
  as a Lender
   
  By: /s/ Ramachandra Rao G.
  Name:  Ramachandra Rao G.
  Title: Vice President and Head Credit

 

UNITED THERAPEUTICS CORPORATION
SECOND AMENDMENT TO CREDIT AGREEMENT

 

 

 

  JPMorgan Chase Bank, N.A.,
  as a Lender
   
  By: /s/ Erik Barragan
  Name:  Erik Barragan
  Title: Authorized Officer

 

UNITED THERAPEUTICS CORPORATION
SECOND AMENDMENT TO CREDIT AGREEMENT

 

 

 EX-101.SCH 4 uthr-20201201.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 uthr-20201201_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 uthr-20201201_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 tm2037326d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001082554 2020-12-01 2020-12-01 iso4217:USD shares iso4217:USD shares 0001082554 false 8-K 2020-12-01 United Therapeutics Corporation DE 000-26301 52-1984749 1040 Spring Street Silver Spring MD 20910 301 608-9292 false false false false Common Stock, par value $0.01 per share UTHR NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover
Dec. 01, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 01, 2020
Entity File Number 000-26301
Entity Registrant Name United Therapeutics Corporation
Entity Central Index Key 0001082554
Entity Tax Identification Number 52-1984749
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1040 Spring Street
Entity Address, City or Town Silver Spring
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20910
City Area Code 301
Local Phone Number 608-9292
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol UTHR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://unither.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2037326d1_8k.htm tm2037326d1_ex10-1.htm tm2037326d1_ex10-2.htm uthr-20201201.xsd uthr-20201201_lab.xml uthr-20201201_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2037326d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2037326d1_8k.htm" ] }, "labelLink": { "local": [ "uthr-20201201_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "uthr-20201201_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "uthr-20201201.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "uthr", "nsuri": "http://unither.com/20201201", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2037326d1_8k.htm", "contextRef": "From2020-12-01to2020-12-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://unither.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2037326d1_8k.htm", "contextRef": "From2020-12-01to2020-12-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001104659-20-131240-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-20-131240-xbrl.zip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end